Recurrent SLC1A2 variants cause epilepsy via a dominant negative mechanism
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
SLC1A2 is a trimeric transporter essential for clearing glutamate from neuronal synapses. Recurrent de novo SLC1A2 missense variants cause a severe, early onset developmental and epileptic encephalopathy via an unclear mechanism. We demonstrate that all 3 variants implicated in this condition localize to the trimerization domain of SLC1A2, and that the Leu85Pro variant acts via a dominant negative mechanism to reduce, but not eliminate, wild‐type SLC1A2 protein localization and function. Finally, we demonstrate that treatment of a 20‐month‐old SLC1A2‐related epilepsy patient with the SLC1A2‐modulating agent ceftriaxone did not result in a significant change in daily spasm count. ANN NEUROL 2019;85:921–926.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
β-Lactam antibiotics offer neuroprotection by increasing glutamate transporter expression
Rothstein, J. D., Patel, S., Regan, M. R., Haenggeli, C., Huang, Y. H., Bergles, D. E., Jin, L., Dykes Hoberg, M., Vidensky, S., Chung, D. S., et al. (2005) · Nature · doi:10.1038/nature03180 · Cited by 1,518
De novo mutations in epileptic encephalopathies
Epi4K Consortium, & Epilepsy Phenome/Genome Project (2013) · Nature · doi:10.1038/nature12439 · Cited by 1,514
Petr, G. T., Sun, Y., Frederick, N. M., Zhou, Y., Dhamne, S. C., Hameed, M. Q., Miranda, C., Bedoya, E. A., Fischer, K. D., Armsen, W., et al. (2015) · The Journal of Neuroscience · doi:10.1523/jneurosci.4255-14.2015 · Cited by 297 · cited 1×
“Pan-knockout or astrocyte-specific knockout of Slc1a2 in mice results in neuronal excitotoxicity, epilepsy, and premature death.(3,4) Despite the severe epilepsy phenotype of homozygous Slc1a2 knockout mice, mice heterozygous for the Slc1a2 deletion demonstrate no apparent clinical phenotype.”
BackgroundSelf-citationDe Novo Mutations in SLC1A2 and CACNA1A Are Important Causes of Epileptic Encephalopathies
Myers, C. T., McMahon, J. M., Schneider, A. L., Petrovski, S., Allen, A. S., Carvill, G. L., Zemel, M., Saykally, J. E., LaCroix, A. J., Heinzen, E. L., et al. (2016) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2016.06.003 · Cited by 287
Cited by
Developmental and epileptic encephalopathies: from genetic heterogeneity to phenotypic continuum
Guerrini, R., Conti, V., Mantegazza, M., Balestrini, S., Galanopoulou, A. S., & Benfenati, F. (2023) · Physiological Reviews · doi:10.1152/physrev.00063.2021 · Cited by 196
Green, J. L., dos Santos, W. F., & Fontana, A. C. K. (2021) · Biochemical Pharmacology · doi:10.1016/j.bcp.2021.114786 · Cited by 150
Gene variations of glutamate metabolism pathway and epilepsy
Feng, Y., Zhang, C., Wei, Z., Li, G., Gan, Y., Liu, C., & Deng, Y. (2022) · Acta Epileptologica · doi:10.1186/s42494-022-00103-2 · Cited by 10
“In treatment, if it is determined that the mutation leads to haploinsufficiency, earlier initiation of SLC1A2-modulating agents may be efficacious to overcome the cumulative dominant negative effects of the variant SLC1A2 allele [32].”
BackgroundTau Ablation Rewires Brain Cell Programs in Health and Restores Function in Disease
Chimal-Juárez, E., Patel, H., Jury-Garfe, N., Dabin, L. C., Vidal, R., Kim, J., & Lasagna-Reeves, C. A. (2026) · bioRxiv · doi:10.64898/2026.05.12.724684
Metadata
- Authors
- Stergachis, A. B., Pujol‐Giménez, J., Gyimesi, G., Fuster, D., Albano, G., Troxler, M., Picker, J., Rosenberg, P. A., Bergin, A., Peters, J., El Achkar, C. M., Harini, C., Manzi, S., Rotenberg, A., Hediger, M. A., & Rodan, L. H.
- Venue
- Annals of Neurology
- Publisher
- Wiley
- Published
- 2019-04-26
- Volume
- 85
- Issue
- 6
- Pages
- 921-926
- ISSN
- 0364-5134 (ISSN-L)
- 1531-8249
- OpenAlex
- W2933696521
- Cited by
- 29
- References
- 4
- FWCI
- 3.16
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.